Despite modest improvements in OS, PFS, and ORR, the NCT00680901 study concluded that the incorporation of lapatinib to capecitabine plus oxaliplatin did not yield any improved OS benefits in previously untreated patients with advanced or metastatic HER2-positive GC/GEJC. Here, ERBB2 is linked to gastric cancer.